Cell and gene therapy sector remains strong despite challenges: ARM CEO The cell and gene therapy sector is “quite strong” despite the regulatory, investment, and manufacturing challenges facing the industry, according to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM). Lambert spoke with ScienceBoard.net about developments in the industry.Read More
Life sciences industry’s search for talent is becoming more challenging: study While more professionals are engaged in life sciences research in the U.S. and a record number of people are graduating in the biological and biomedical sciences, the ability of employers to find life sciences research talent is proving extremely difficult, according to a new report from CBRE.Read More
The ‘voice of the patient’ needs to be heard in clinical trials: study Patient recruitment and retention are among the biggest challenges facing clinical research, particularly in studies targeting rare diseases that have a limited pool of patients, contends Clincierge CEO Scott Gray. He spoke with ScienceBoard.net about Clincierge's study examining the patient experience in clinical trials of rare diseases.Read More
Biotech innovator recounts decades-long journey to create drug discovery technology Dr. Stan Crooke, PhD, founder, chairman, and chief executive officer of RNA therapy company Ionis Pharmaceuticals, pioneered development of the antisense technology platform and created one of the largest, most advanced pipelines in the biotech industry. Crooke shared his story in an interview with ScienceBoard.net.Read More
11.7T MR spectroscopy quantifies brain glucose metabolism French researchers have developed a new MR (magnetic resonance) spectroscopy approach to study brain glucose metabolism, a process significantly involved in Alzheimer's disease. They presented their work in an animal study at the annual meeting of the International Society for Magnetic Resonance in Medicine.Read More
Manufacturing partnerships support high quality cell therapies Chimeric Therapeutics, Ncardia, and Novartis are some of the companies that have decided to partner to make complex manufacturing processes more efficient for novel therapies, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard.Read More